secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theriva Biologics, Inc. (TOVX)
CIK:        0000894158
Form:       8-K
Filed at:   2026-08-04T11:20:18+00:00
Accession:  0001104659-26-090064
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theriva Biologics shareholders approve 2M share increase in stock plan, reelect directors at 2026 annual meeting
--------------------------------------------------------------------------------

- Shareholders approved Amendment No. 4 to 2020 Stock Incentive Plan, increasing shares from 4.5M to 6.5M.
- All four director nominees elected: Kraws, Shallcross, Monahan, Wolf.
- Ratified BDO USA as independent auditor for FY2026.
- Approved charter amendment to increase authorized shares; Board has discretion to file.
- Approved issuance of common stock upon exercise of outstanding warrants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/894158/000110465926090064/0001104659-26-090064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/894158/000110465926090064/tm2619846d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-090064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer